LM-302 is under clinical development by Bristol-Myers Squibb and currently in Phase I for Esophageal Cancer. According to GlobalData, Phase I drugs for Esophageal Cancer have an 80% phase transition ...

Vemurafenib is under clinical development by F. Hoffmann-La Roche and currently in Phase II for Craniopharyngioma. According to GlobalData, Phase II drugs for Craniopharyngioma does not have ...

Vemurafenib is under clinical development by F. Hoffmann-La Roche and currently in Phase II for Sarcomas. According to GlobalData, Phase II drugs for Sarcomas have a 27% phase transition success rate ...

FP-045 is under clinical development by Foresee Pharmaceuticals and currently in Phase II for Fanconi Anemia. According to GlobalData, Phase II drugs for Fanconi Anemia does not have sufficient ...

Odronextamab is under clinical development by Regeneron Pharmaceuticals and currently in Phase III for Marginal Zone B-cell Lymphoma.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

Denosumab biosimilar is under clinical development by Samsung Bioepis and currently in Phase III for Post Menopausal Osteoporosis.

Odronextamab is under clinical development by Regeneron Pharmaceuticals and currently in Phase II for Diffuse Large B-Cell Lymphoma.

Satralizumab is under clinical development by F. Hoffmann-La Roche and currently in Phase III for Demyelinating Diseases.

XBiotech has said it will investigate the results of its rheumatoid arthritis trial after finding irregularities in its Phase II trial.